anti-Leucine Zipper, Down-Regulated in Cancer 1 (LDOC1) Antibodies

Human Leucine Zipper, Down-Regulated in Cancer 1 (LDOC1) interaction partners

1. LDOC1 is a tumor suppressor in Colorectal cancer (CRC) and it inhibits cell proliferation and promotes cell apoptosis. Additionally, it inhibits CRC cell metastasis by downregulating the Wnt/betacatenin signaling pathway.

2. that epigenetic silencing of LDOC1 in high-risk Group A ependymoma regulates tumor biology and drives inflammatory immune phenotype

3. GNL3L-LDOC1 interplay regulates cell proliferation through the modulation of NF-kappaB pathway during tumorigenesis.

4. These finding of this study suggested that the hypothesize that LDOC1 gene upregulation may play a role in the spermatogenesis derangement observed in patients with Klinefelter Syndrome.

5. data show that LDOC1 is a tumor suppressor in osteosarcoma, and that it regulates metastasis of osteosarcoma cells. Furthermore, LDOC1 might be a valuable prognostic marker in osteosarcomas.

6. Cigarette smoke-induced promoter methylation may contribute to LDOC1 downregulation, thereby conferring oncogenic features to oral cells.

7. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-kappaB activation in papillary thyroid carcinoma

8. It has potential roles in apoptosis of well differentiated carcinoma without metastases and in neurodegeneration of Alzheimer's disease.

9. Silencing of LDOC1 is a frequent event in cervical cancer and may be of interest as a molecular marker in cervical cancer.

10. Silencing of BEX1 and LDOC1 by promoter hypermethylation might represent a critical event in the molecular pathogenesis of oral squamous cell carcinoma (OSCC) and the male predominance of OSCC occurrence.

11. Letter/Case Report: LDOC1/PARP1 are down-regulated in melanoma with repeated in-transit metastases.

12. The aim of this study was to evaluate the possible differential expression of LDOC1 mRNA in leucocytes of peripheral blood of Down's syndrome subjects. compared with the normal population.

13. Over expression of LDOC1 may explain the clinical manifestation found in patients with cryptochidism and Digeorge anomaly.

14. LDOC1 is dramatically down-regulated in mutated chronic lymphocytic leukemia cases compared with unmutated cases, and have identified a new splice variant, LDOC1S

15. These observations suggest that LDOC1 is a novel regulator of NF-kappaB that can affect the PMA or TNF-alpha-mediated pathway to apoptosis through inhibition of NF-kappaB activation in BxPC3 pancreatic cancer cells.

16. MZF-1 was revealed to interact with LDOC1 and enhance the activity of LDOC1 for inducing apoptosis